1 Pancheri P.
Schizofrenia: Sintomi, sindromi, dimensioni.
G Ital Psicopatol 1996;1:1-3.

2 Pancheri P, Marconi PL.
Le dimensioni della schizofrenia.
G Ital Psicopatol 1996;1:10-41.

3 Sokoloff P, Giros B, Martres MP.
Localization and function of the D3 dopamine receptor.
Arzneimittelforschung 1992;42:224-30.

4 Kramer MS, Last B, Getson A, Reines SA.
The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic impatients with schizophrenia.
Arch Gen Psychiatry 1997;54:567-72.

5 Gurevich EV, Joyce JN.
Distribution of dopamine D3 receptors expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons.
Neuropsychopharmacology 1999;20:60-80.

6 Coukell AJ, Spencer CM, Benfield P.
Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia.
CNS Drugs 1996;6(3):237-56.

7 Patat A, Rosenzweig P, Miget N, Allain H, Gandon JM.
Effects of 50 mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep deprived subjects.
Found Clin Pharmacology 1999;13:582-94.

8 Delle Chiaie R, Caliari P.
La sintomatologia depressiva attenuata: razionale per l'uso dell'amisulpride nella distimia e nelle depressioni subsindromiche.
Cervello e Farmaci 1998;34:5-21.

9 Boyer P.
Amisulpride in the treatment of negative schizophrenic symptoms: results of a doubleblind controlled trial versus a placebo.
In: Borenstein P, Boyer P, Braconnier A, et al. Amisulpride Expansion Scientifique Française, Paris 1989.

10 Chivers JK, Gommeren W, Leysen JE, Jenner P.
Comparison of the in vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.
J Pharmacol 1988;40:415-21.

11 Schoemaker H, Claustre Y, Fage D.
Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
J Pharmacol Exp Ther 1997;280:83-97.

12 Scatton B, Perrault G, Gonon F.
Novel neuroloptics acting on presynaptic dopaminergic receptors [astr. N° S-19-1].
Neuropsychopharmacology 1995;5(spec iss):214.

13 Vasse M, Protals P, Costentin J.
Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviors elicited by dopamine agonists in mice.
Naunyn Schmiedebergs Arch Pharmacol 1985;329:108-16.

14 Vasse M, Protais P.
Potentiation of apomorphine-induced stereotyped behavior by acute treatment with dopaminedepleting agents: apotential role for an increased stimulation of D1 dopamine receptors.
Neuropharmacology 1989;28:931-9.

15 Vesse M, Potrais P.
Increased grooming behavior is induced by apomorphine in mice treated with discriminant benzamide derivates.
Eur J Pharmacology 1988;156:1-11.

16 Guyon A, Assouly-Besse F, Biala G.
Potentiation by low doses of selected neuroleptics of food induced conditioned place preference in rats.
Psychopharmacology 1993;110:460-6.

17 Scatton B, Perrault G, Sanger DJ.
Pharmacological profile of amisulpride, an atypical neuroleptic which preferentially blocks pre-synaptic D2/D3 receptors.
Neuropsychopharmacology 1994;10(suppl.1):242S.

18 Martres MP, Sokoloff P, Delandre M.
Selection of dopamine antagonists discriminating various behavior responses and radioligand binding sites.
Naunyn Schmiedebergs Arch Pharmacol 1984;325:102-15.

19 Protals P, Hermier C, Costentin J.
The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration.
Neuropharmacology 1985;24:861-7.

20 Martinot JL, Paillère-Martinot ML, Poirier MF.
In vivo charachteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.
Psychopharmacology 1996;124:154-8.

21 Schwartz JC, Levesque D, Martres MP.
Dopamine D3 receptor: Basic and clinical aspects.
Clin Neuropharmacol 1993;16:295-314.

22 Wetzel H, Wiesner J, Hiemke C.
Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers.
J Psychiatry Res 1994;28:461-73.

23 Wetzel H, Grunder, Riemann M.
Amisulpride: effects on nocturnal hormone secretion and sieep EEG parameters in healthy young volunteers.
Pharmacopsychiatry 1993;25:93.

24 Mattila MJ, Seppala T, Patat A.
Oral single doses of amisulpride do not interact with ethanol on performance and memory.
Br J Clin Pharmacol 1995;41:454.

25 Bianchetti G, Canal M, Rosenweig P.
Amisulpride: summary of human pharmacology and pharmacokinetics studies.
Synthelabo Groupe. Report n. 95 00679-EN-00. (Data on file).

26 Weinberger DE, Berman KF, Illowsky BP.
Physiologic dysfunction of dorsolateral prefrontal cortex in schizofrenia. III. A new cohort and evidence of monoaminergic mechanism.
Arch Gen Psychiatry 1988;45:609-15.

27 Pichot P, Boyer P.
A double blind, controlled multicenter trial of amisulpride versus high dose haloperidol in acute psychotic disorders.
Ann Psychiatr 1988;3,3Bis:326-32.

28 Delcker A, Schoon ML, Oczkowski B, Gaertner HJ.
Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study.
Pharmacopsychiatry 1990;23,5:125-30.

29 Möller HJ, Boyer P, Fleurot O, Rein W.
Improvement of acute exacerbations of schizophrenia with Amisulpride: a comparison with haloperidol.
Psychopharmacology 1997;132:396-401.

30 Puech A, Fleurot O, Rein W and the Amisulpride Study Group.
Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol.
Acta Psychiatr Scand 1998;98:65-72.

31 Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adier G, Shroder J, Rein W, Benkert O.
Amisulpride vs. Flupentixol in the treatment of schizophrenia with predominant positive symptomathology: A controlled double blind study.
Psychopharmacology 1998;137:223-32.

32 Freeman HL.
Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Int Clin Psychopharmacol 1997;12(suppl.2):s11-7.

33 Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W.
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia.
Psychiatry Res 1999;88:107-17.

34 Möller HJ, van Praag HM, Aufdembrinke B.
Negative symptoms in schizophrenia: Considerations for clinical trials.
Psychopharmachology 1994;115:221-8.

35 Pichot R, Boyer P.
A double blind-controlled, multicenter trial of low dose amisulpride versus low dose phluphenazine in the treatment of negative symptoms in chronic schizophrenia.
Ann Psychiatr 1988;3(3)bis:312-20.

36 Saletu B, Ktifferle B. Gronberger J, et al.
Clinical. EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
Neuropsychobiology 1994;29:125-35.

37 Bogetto F, Fonzo V, Maina G.
Adjunctive fluoxetine or amisulpride improves schizophrenic negative symptoms.
Eur J Psychiatry 1995;9:119-26.

38 Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F.
Treatment of negative symptoms in schizophrenia with amisulpride.
Br J Psychiatry 1995;166:68-72.

39 Paillère-Martinot ML, Lecrubier Y, Martinot JL, Aubin F.
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.
Am J Psychiatry 1995;152:130-34.

40 Danion JM, Rein W, Fleurot O.
Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride.
Am J Psychiatry 1999;156:610-6.

41 Loo H, Porierr-Litre MF, Theron M, Rein W, Fleurot O.
Amisulpride vs placebo in the medium term treatment of negative symptoms of schizophrenia.
Br J Psychiatry 1997;170:18-22.

42 Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL.
One year low dose neuroleptic study of in patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride vs. haloperidol.
Br J Psychiatry 1997;171:564-8.

43 Rein W, Favennec-Meidinger C.
Amisulpride clinical textual summary (IV B).
Synthelabo Groupe (Le Plessis-Robinson, France). 1995, Report n. 95-00854-EN-00. (Data on file).

44 Colonna L, Saleem P, Dondey-Nouvel L, Rein W.
Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia.
Int Clin Psychopharmacol 1999;14:214-25.

45 Rein W, Turjanski S.
Clinical update on amisulpride in deficit schizophrenia.
Int Clin Psychopharmacol 1997;12(suppl.2):S19-27.

46 Mecheri G, Marie Cardine-M, Terra JL.
Open trial of amisulpride on negative symptoms of schizophrenia: report of nine cases.
Psychol Med 1993;25:347-55.

47 Terra IL, Chatard JP, Dufour H, et al.
Value of amisulpride in schizophrenia with negative symptoms. Results of an open, multicenter trial as single-drug therapy.
Sem Hop 1990;66:251-3.

48 Mecheri G, Marie Cardine-M, Terra JL.
Open trial of amisulpride on negative symptoms of schizophrenia: report of nine cases.
Psychol Med 1993;25:347-55.

49 Singer L, Danion JM.
Therapeutic value of low doses of amisulpride in the treatment of schizophrenia where negative symptoms predominate.
J Med Strasbourg 1990;21:344-8.

50 Valva G, Thomas P, Dutoit D.
Low doses of amisulpride in negative schizophrenia: a 99m-Tc HMPAO SPECT study.
Eur Neuropsychopharmacol 1995;5(special issue):336.

51 Benkert O.
Data on File. Synthelabo Recherche.